September 2018 tender notification

Tender Closed

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender, dated 3 November 2016 and the 2017/18 Invitation to Tender, dated 2 November 2017.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand
(Supplier)

Date of subsidy change

Sole Subsidised Supply date

Colchicine

Tab 500 mcg, 100 tablet, bottle pack

$10.08

$9.58

Colgout
(Aspen Pharma)

1 November 2018

1 February 2019

Ferrous fumarate

Tab 200 mg (65 mg elemental), 100 tablet, blister pack

$2.89

$3.09

Ferro-tab
(AFT)

1 November 2018

1 February 2019

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Hospital supply brand
(Supplier)

DV
Limit

Date of subsidy change

Hospital Supply Status date

Colchicine

Tab 500 mcg, 100 tablet, bottle pack

$10.08

$9.58

Colgout
(Aspen Pharma)

1%

1 November 2018

1 January 2019

Doxorubicin hydrochloride1

Inj 2 mg per ml, 100 ml vial, 1 vial pack

$46.00

$56.15

Doxorubicin Ebewe
(Novartis)

1%

1 November 2018

1 January 2019

Ferrous fumarate

Tab 200 mg (65 mg elemental), 100 tablet, blister pack

$2.89

$3.09

Ferro-tab
(AFT)

1%

1 November 2018

1 January 2019

1 The price and subsidy of Doxorubicin hydrochloride inj 2 mg per ml, 100 ml vial in Section B of the Pharmaceutical Schedule will also be amended from 1 November 2018. The subsidy for doxorubicin hydrochloride inj 1 mg for ECP (Baxter) in Section B of the Pharmaceutical Schedule will change from $0.25 per 1 mg to $0.29 per 1 mg from 1 January 2019.

3. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current pack price

New pack price

Hospital supply brand (Supplier)

DV Limit

Listing date

Hospital Supply Status date

Brand (Supplier) affected by delisting

Carboplatin1

Inj 10 mg per ml, 45 ml vial, 1 vial pack

$32.59

$45.20

Carboplatin Ebewe
(Novartis)

1%

1 April 2019

1 June 2019

DBL Carboplatin
(Pfizer)

Linezolid

Inj 2 mg per ml, 300 ml bottle, 1 solution for injection

$1,650.00
per 10

$18.50 per 1

Linezolid Kabi
(Fresenius Kabi)

1%

1 December 2018

1 February 2019

Zyvox
(Pfizer)

 1 The price and subsidy of Carboplatin inj 10 mg per ml, 45 ml vial in Section B of the Pharmaceutical Schedule will also be amended to the above price from 1 April 2019. The subsidy for carboplatin inj 1 mg for ECP (Baxter) in Section B of the Pharmaceutical Schedule will change from $0.08 per 1 mg to $0.10 per 1 mg from 1 June 2019.        

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

  • the 2016/17 Invitation to Tender, dated 3 November 2016, and
  • the 2017/18 Invitation to Tender, dated 2 November 2017.

2016/17 Invitation to Tender

Chemical name

Line item

Buprenorphine with naloxone

Tab sublingual 2 mg with naloxone 0.5 mg

Buprenorphine with naloxone

Tab sublingual 8 mg with naloxone 2 mg

Cetirizine hydrochloride

Oral liq 1 mg per ml

2017/18 Invitation to Tender

Chemical name

Line item

Benzoyl peroxide

Soln/Gel 5%

Carboplatin

Inj 10 mg per ml, 15 ml

Hydrocortisone butyrate

Lipocream 0.1% (pack size 30 g or less)

Hydrogen peroxide

Soln 3% (10 vol)

Imipenem with cilastatin

Inj 500 mg with cilastatin 500 mg

Oxaliplatin

Inj 50 mg

For products included in the 2016/17 and 2017/18 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.